Shire Human Genetic Therapies and Amicus Therapeutics entered into license agreement for Amicus’ products - Amigal™ (migalastat hydrochloride) for treating Fabry’s disease and Plicera™ (isofagomine tartrate) for treating Gaucher’s disease, both of which are in phase 2 clinical trials and AT2220 which is in phase 1 clinical trials for treating Pompe disease. The deal would worth up to US$490 M to Amicus.